A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Inclusion Criteria:

1. Histologically confirmed diffuse large B-cell lymphoma (DLBCL).

2. Have received ≥1 line of systemic antitumor therapy.

3. At least one bi-dimensionally measurable lesion.

4. Expected survival of at least 3 months.

5. Age ≥18 years old and under 80 years old.

6. The patients voluntarily participated in the study, signed informed consent, hadgood compliance and were willing to cooperate with follow-up.

Exclusion Criteria:

1. Central nervous system lymphoma involvement.

2. Primary mediastinal (thymus) large B-cell lymphoma.

3. Patients who have only one prior line therapy and are candidates for stem celltransplantation.

4. A history of immunodeficiency.

5. A history of severe cardiovascular disease.

6. A history of other malignancies within 5 years prior to administration of the firstdose.